MAY 11, 2020 11:27 AM PDT

Using Deep Learning to Diagnose Breast Cancer Sub-Types

WRITTEN BY: Jasper Cantrell

Cancer and computer programming may not sound like two things that go together. However, advanced programming techniques are now able to utilize large data training sets and “learn” how to solve problems. This is called machine learning. This technique is often used in things like search engine refinement, ad targeting, and even simple artificial intelligence programs. A group from California proposed that deep learning, a form of machine learning, could be used to diagnose the sub-clinical types of breast cancer.

The hypothesis was that deep learning might be able to identify histological differences between estrogen, progesterone, and Her2 (ER/PR/Her2) receptor-based breast cancers. Each of these sub-types has minor characteristic differences and sometimes different treatment paths. Current diagnostic methods involve immunohistochemistry against the receptors. The deep learning program would focus on the analysis of a sample's histology using hematoxylin and eosin (H&E) images to predict the sample’s sub-clinical typing. Histological characteristics are not usually used to diagnose the sub-types as the interpretation of a sample could easily differ between doctors. The program would be able to overcome this bias.

The first step was to obtain a set of data for the deep learning program to use to train itself. Finding this dataset itself was a bit of a challenge, due to many H&E images available not being properly labeled. Initially, they ordered tissue microarrays (TMA), each with 207 samples, and put them through a set of four experiments. Experiments one and two used microarrays that had been stained by the lab, with the first experiment being only 207 samples, and the second having twenty fold more samples. The last two experiments were the same, except with the sample images colors normalized. This was done to try and make the program identify sub-types regardless of the coloration of the H&E image. The high sample normalized dataset from experiment four gave the best accuracy result at 93% correct after correcting for data bias.

Spurred on by the positive results, the group decided to test the same methodology to develop a second neural network using H&E breast cancer images from The Cancer Genome Atlas. The resulting program could predict the correct sub-clinical typing about 88% of the time. When this network was used on separate data from the Australian Breast Cancer Tissue Bank, it maintained around an 80% accuracy in its prediction of all three sub-types. They had successfully developed a new neural network that could predict the sub-type of breast cancers.

In their discussion, the team states, “Here, we illustrate a novel first step, using tissue matching to discern features that are distinctive for a patient but differ between individuals.” This implementation, once properly vetted for reliability, could aid researchers in identifying the best treatment for their breast cancer patients. It may even help pave the road for the increased use of advanced computer programs in healthcare work, which could propel healthcare into the not so far-flung future.

Sources: Nature, The Medical Futurist

 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUL 21, 2020
Cancer
Colorectal cancer screening kits delivered to you through the mail
JUL 21, 2020
Colorectal cancer screening kits delivered to you through the mail
New research published in the American Cancer Society’s CANCER says that improving screening rates for colorectal ...
JUL 30, 2020
Cardiology
Protecting the Heart Against Cardiotoxicity
JUL 30, 2020
Protecting the Heart Against Cardiotoxicity
Doxorubicin is a potent chemotherapy drug used for many different cancers. Unfortunately, like all chemotherapies, doxor ...
AUG 05, 2020
Immunology
Intercepting Cancer Cells Before They Can Dodge the Immune System
AUG 05, 2020
Intercepting Cancer Cells Before They Can Dodge the Immune System
The battle that naturally occurs between the body’s immune system and cancerous cells is one that scientists have ...
AUG 28, 2020
Cancer
Using CRISPR-Cas12a to Repair Hereditary Cancers in the Lab
AUG 28, 2020
Using CRISPR-Cas12a to Repair Hereditary Cancers in the Lab
Genome repair is one of the big-ticket research areas for the future of medicine. CRISPR-Cas9 systems can edit the genom ...
SEP 06, 2020
Cancer
Focal HIFU ablation improves prostate cancer patients' quality of life
SEP 06, 2020
Focal HIFU ablation improves prostate cancer patients' quality of life
Research published in The Journal of Urology offers an alternative to invasive prostate cancer treatments like surg ...
SEP 21, 2020
Cancer
Black women have delayed and longer breast cancer treatment
SEP 21, 2020
Black women have delayed and longer breast cancer treatment
A study led by UNC Lineberger Comprehensive Cancer Center researchers has quantified the healthcare inequities in cancer ...
Loading Comments...